CS 6253

Drug Profile

CS 6253

Alternative Names: Cogpep™; CS6253

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at Berkeley
  • Developer Artery Therapeutics; Tel Aviv University; University of California at Berkeley
  • Class Neuropeptides
  • Mechanism of Action ATP binding cassette transporter 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Atherosclerosis; Type 2 diabetes mellitus

Most Recent Events

  • 30 Aug 2017 New profile created from abstract 3267616
  • 26 Aug 2017 Pharmacodynamics data from preclinical trials in Alzheimer's disease presented at the Annual Congress of the European Society of Cardiology (ESC Congress 2017)
  • 26 Aug 2017 Preclinical trials in Atherosclerosis in USA (SC) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top